Krystal Biotech/$KRYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Krystal Biotech
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Ticker
$KRYS
Sector
Primary listing
Employees
295
Headquarters
Website
Krystal Biotech Metrics
BasicAdvanced
$8.9bn
40.45
$7.47
0.49
-
Price and volume
Market cap
$8.9bn
Beta
0.49
52-week high
$319.48
52-week low
$122.80
Average daily volume
296k
Financial strength
Current ratio
9.459
Quick ratio
8.816
Long term debt to equity
0.573
Total debt to equity
0.714
Profitability
EBITDA (TTM)
180.468
Gross margin (TTM)
94.17%
Net profit margin (TTM)
53.92%
Operating margin (TTM)
42.83%
Effective tax rate (TTM)
-8.54%
Revenue per employee (TTM)
$1,410,000
Management effectiveness
Return on assets (TTM)
9.04%
Return on equity (TTM)
19.90%
Valuation
Price to earnings (TTM)
40.448
Price to revenue (TTM)
21.036
Price to book
6.96
Price to tangible book (TTM)
6.96
Price to free cash flow (TTM)
36.979
Free cash flow yield (TTM)
2.70%
Free cash flow per share (TTM)
8.168
Growth
Revenue change (TTM)
25.15%
Earnings per share change (TTM)
79.70%
3-year earnings per share growth (CAGR)
12.27%
What the Analysts think about Krystal Biotech
Analyst ratings (Buy, Hold, Sell) for Krystal Biotech stock.
Krystal Biotech Financial Performance
Revenues and expenses
Krystal Biotech Earnings Performance
Company profitability
Krystal Biotech News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs